Jones Financial Companies Lllp Buys 14,948 Shares of CRISPR Therapeutics AG $CRSP

Jones Financial Companies Lllp boosted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 50.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 44,715 shares of the company’s stock after buying an additional 14,948 shares during the period. Jones Financial Companies Lllp’s holdings in CRISPR Therapeutics were worth $2,758,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Orbis Allan Gray Ltd increased its stake in shares of CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares during the period. Geode Capital Management LLC grew its holdings in CRISPR Therapeutics by 98.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company’s stock valued at $100,789,000 after buying an additional 1,025,979 shares in the last quarter. State Street Corp increased its position in CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after buying an additional 859,334 shares during the period. Norges Bank bought a new position in CRISPR Therapeutics during the 2nd quarter worth $19,772,000. Finally, Jump Financial LLC bought a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $17,331,000. 69.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Wells Fargo & Company set a $75.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, October 13th. Chardan Capital dropped their price target on shares of CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating for the company in a research report on Wednesday, November 26th. Robert W. Baird reduced their price target on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Royal Bank Of Canada raised their price objective on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Twelve equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $67.85.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the sale, the chief executive officer directly owned 134,201 shares of the company’s stock, valued at approximately $8,082,926.23. The trade was a 30.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $48.74 on Monday. The business has a fifty day moving average price of $54.74 and a two-hundred day moving average price of $57.79. The stock has a market capitalization of $4.64 billion, a PE ratio of -8.72 and a beta of 1.72. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The company had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $8.74 million. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.